Investigational drug · Phase 2
Dusquetide
Also called: SGX945, SGX942
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Behçet Disease.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "Dusquetide"
First trial start
2024
Nov 18, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Dusquetide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Behçet Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Dusquetide" as an intervention, largest first.
- DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck CancerPivotal-lookingCompleted
SoligenixIndustry
NCT03237325 · 266 participants · Start Dec 4, 2017 · Primary completion Jun 24, 2020
Drug: SGX942; Placebo · For: Squamous Cell Carcinoma of the Oral Cavity and Oropharynx; Oral Mucositis
Sites: Tucson, Arizona; Loma Linda, California; Pomona, California · 53 sites in all
SoligenixIndustry
NCT06386744 · 8 participants · Start Nov 18, 2024 · Primary completion May 23, 2025
Drug: Dusquetide · For: Behçet Disease
Sites: Istanbul, Turkey (Türkiye)
Newest research
PubMed records naming it or its code names, newest first.
- Behçet's syndrome: one year in review 2026.
Hatemi G, Seyahi E, Fresko I, et al. · Clin Exp Rheumatol 2026
- Dusquetide Regulates SQSTM1/p62-Mediated Mitophagy to Alleviate PM2.5-Aggravated Airway Inflammation in Asthma.
Gao J, Liu JL, Jiang ML, et al. · Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2026
- Results from a pilot study of dusquetide for the treatment of aphthous ulcers associated with Behçet's syndrome.
Donini O, Sulu B, Pullion C, et al. · Rheumatology (Oxford) 2026
- Comparisons of successful and failed Phase III trials of drugs and biologicals tested for mitigation of oral mucositis in patients being treated with radiotherapy with or without concomitant chemotherapy for cancers of the head and neck.
Liang L, Sonis ST · Drug Dev Res 2024
- Linker-Free Synthesis of Antimicrobial Peptides Using a Novel Cleavage Reagent: Characterisation of the Molecular and Ionic Composition by nanoESI-HR MS.
Segovia R, Díaz-Lobo M, Cajal Y, et al. · Pharmaceutics 2023
- Protocol to identify drug-binding sites in proteins using solution NMR spectroscopy.
Penumutchu S, Liu J, Singh UK, et al. · STAR Protoc 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.